DexCom(US:DXCM) Globenewswire·2025-12-23 00:29Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its products, particularly the G6 and G7 glucose monitoring devices, during the class period from July 26, 2024, to September 17, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased DexCom securities during the specified class period [2]. - Investors have until December 26, 2025, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 devices that were not approved by the FDA, which compromised their reliability and posed health risks to users [3]. - It is claimed that the enhancements to the G7 were overstated, and the company downplayed the severity of issues related to the devices, leading to increased regulatory scrutiny and potential legal repercussions [3]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the claims are encouraged to contact the law firm for further details and assistance [4].